Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

192 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antecedent angina pectoris predicts worse outcome after myocardial infarction in patients receiving thrombolytic therapy: experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Barbash GI, White HD, Modan M, Van de Werf F. Barbash GI, et al. Among authors: modan m. J Am Coll Cardiol. 1992 Jul;20(1):36-41. doi: 10.1016/0735-1097(92)90134-9. J Am Coll Cardiol. 1992. PMID: 1607536 Free article. Clinical Trial.
Rapid resolution of ST elevation and prediction of clinical outcome in patients undergoing thrombolysis with alteplase (recombinant tissue-type plasminogen activator): results of the Israeli Study of Early Intervention in Myocardial Infarction.
Barbash GI, Roth A, Hod H, Miller HI, Rath S, Har-Zahav Y, Modan M, Seligsohn U, Battler A, Kaplinsky E, et al. Barbash GI, et al. Among authors: modan m. Br Heart J. 1990 Oct;64(4):241-7. doi: 10.1136/hrt.64.4.241. Br Heart J. 1990. PMID: 2121199 Free PMC article. Clinical Trial.
Outcome of thrombolytic therapy in relation to hospital size and invasive cardiac services. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EA, Van der Werf T, et al. Barbash GI, et al. Among authors: modan m. Arch Intern Med. 1994 Oct 10;154(19):2237-42. Arch Intern Med. 1994. PMID: 7944845 Clinical Trial.
Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Barbash GI, White HD, Modan M, Diaz R, Hampton JR, Heikkila J, Kristinsson A, Moulopoulos S, Paolasso EA, Van der Werf T, et al. Barbash GI, et al. Among authors: modan m. Circulation. 1993 Jan;87(1):53-8. doi: 10.1161/01.cir.87.1.53. Circulation. 1993. PMID: 8419024
Comparative case fatality analysis of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial: variation by country beyond predictive profile. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial.
Barbash GI, Modan M, Goldbourt U, White HD, Van de Werf F. Barbash GI, et al. Among authors: modan m. J Am Coll Cardiol. 1993 Feb;21(2):281-6. doi: 10.1016/0735-1097(93)90664-m. J Am Coll Cardiol. 1993. PMID: 8425987 Free article. Clinical Trial.
Randomized controlled trial of late in-hospital angiography and angioplasty versus conservative management after treatment with recombinant tissue-type plasminogen activator in acute myocardial infarction.
Barbash GI, Roth A, Hod H, Modan M, Miller HI, Rath S, Zahav YH, Keren G, Motro M, Shachar A, et al. Barbash GI, et al. Among authors: modan m. Am J Cardiol. 1990 Sep 1;66(5):538-45. doi: 10.1016/0002-9149(90)90478-j. Am J Cardiol. 1990. PMID: 2118299 Clinical Trial.
192 results